FRM
Fox Run Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $607K | Buy |
+16,689
| New | +$607K | 0.1% | 387 |
|
|
2023
Q3 | – | Sell |
-4,887
| Closed | -$225K | – | 941 |
|
|
2023
Q2 | $225K | Buy |
+4,887
| New | +$225K | 0.06% | 543 |
|
|
2022
Q4 | – | Sell |
-13,355
| Closed | -$553K | – | 840 |
|
|
2022
Q3 | $553K | Buy |
+13,355
| New | +$553K | 0.22% | 139 |
|
|
2022
Q2 | – | Sell |
-5,392
| Closed | -$392K | – | 711 |
|
|
2022
Q1 | $392K | Buy |
+5,392
| New | +$392K | 0.22% | 166 |
|
|
2021
Q3 | – | Sell |
-5,364
| Closed | -$511K | – | 591 |
|
|
2021
Q2 | $511K | Buy |
+5,364
| New | +$511K | 0.46% | 40 |
|
|
2019
Q3 | – | Sell |
-3,214
| Closed | -$204K | – | 524 |
|
|
2019
Q2 | $204K | Buy |
+3,214
| New | +$204K | 0.14% | 368 |
|
|
2018
Q1 | – | Sell |
-11,453
| Closed | -$531K | – | 885 |
|
|
2017
Q4 | $531K | Buy |
11,453
+7,453
| +186% | +$346K | 0.16% | 266 |
|
|
2017
Q3 | $213K | Buy |
+4,000
| New | +$213K | 0.06% | 589 |
|
|
2016
Q1 | – | Sell |
-2,600
| Closed | -$292K | – | 528 |
|
|
2015
Q4 | $292K | Buy |
+2,600
| New | +$292K | 0.23% | 170 |
|